Compare Eli Lilly And Co (LLY) vs Wells Fargo & Co (WFC) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Wells Fargo (WFC) trades at $86.3, down 1.4% on the day, with a bullish technical outlook from moving averages and a consensus analyst price target of $97.36. The bank reported strong Q2 2026 earnings, beating EPS estimates with $1.96 actual versus $1.73 expected, driven by net interest income and fee growth. Revenue trends show steady growth from $83.7B in 2025 to a projected $87.0B in 2026, with net income margins improving to 25.97%. Recent news highlights AI investments in wealth management and a healthy investment banking pipeline.

The outlook for WFC is positive, supported by earnings momentum, dividend payments, and analyst upgrades. Key opportunities include continued revenue growth and efficiency gains post-asset cap removal. Risks involve net interest margin pressure, expense management challenges, and macroeconomic sensitivity. Institutional sentiment is mixed but leans bullish, with 45% of analysts rating it a buy.